BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 29067836)

  • 1. Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials.
    da Silva KR; Costa R; Rodrigues CG; Schasechter A; Nobre MC; Passman R; Mark DB
    Eur J Cardiovasc Nurs; 2018 Mar; 17(3):196-206. PubMed ID: 29067836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II.
    Klein H; Auricchio A; Reek S; Geller C
    Am J Cardiol; 1999 Mar; 83(5B):91D-97D. PubMed ID: 10089848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg . Canadian Implantable Defibrillator Study.
    Connolly SJ; Hallstrom AP; Cappato R; Schron EB; Kuck KH; Zipes DP; Greene HL; Boczor S; Domanski M; Follmann D; Gent M; Roberts RS
    Eur Heart J; 2000 Dec; 21(24):2071-8. PubMed ID: 11102258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.
    Deniz HB; Ward A; Jaime Caro J; Alvarez P; Sadri H
    Curr Med Res Opin; 2009 Mar; 25(3):617-26. PubMed ID: 19232036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial).
    Fishbein DP; Hellkamp AS; Mark DB; Walsh MN; Poole JE; Anderson J; Johnson G; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2014 Jun; 63(23):2560-2568. PubMed ID: 24727258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subanalyses of secondary prevention implantable cardioverter-defibrillator trials: antiarrhythmics versus implantable defibrillators (AVID), Canadian Implantable Defibrillator Study (CIDS), and Cardiac Arrest Study Hamburg (CASH).
    Oseroff O; Retyk E; Bochoeyer A
    Curr Opin Cardiol; 2004 Jan; 19(1):26-30. PubMed ID: 14688631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary prevention of sudden death: the Dutch Study, the Antiarrhythmics Versus Implantable Defibrillator Trial, the Cardiac Arrest Study Hamburg, and the Canadian Implantable Defibrillator Study.
    Cappato R
    Am J Cardiol; 1999 Mar; 83(5B):68D-73D. PubMed ID: 10089843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT.
    Poole JE; Olshansky B; Mark DB; Anderson J; Johnson G; Hellkamp AS; Davidson-Ray L; Fishbein DP; Boineau RE; Anstrom KJ; Reinhall PG; Packer DL; Lee KL; Bardy GH;
    J Am Coll Cardiol; 2020 Jul; 76(4):405-415. PubMed ID: 32703511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of implantable cardioverter-defibrillators.
    Sanders GD; Hlatky MA; Owens DK
    N Engl J Med; 2005 Oct; 353(14):1471-80. PubMed ID: 16207849
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death.
    Au-Yeung WT; Reinhall PG; Poole JE; Anderson J; Johnson G; Fletcher RD; Moore HJ; Mark DB; Lee KL; Bardy GH
    Heart Rhythm; 2015 Oct; 12(10):2058-66. PubMed ID: 26096609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.
    Pun PH; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton AE; Moss AJ; Lee KL; Steinman R; Dorian P; Hallstrom A; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Hess PL; Inoue LY; Sanders GD
    Am J Kidney Dis; 2014 Jul; 64(1):32-9. PubMed ID: 24518128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic Review and Meta-Analysis of Clinical Outcome After Implantable Cardioverter-Defibrillator Therapy in Patients With Chagas Heart Disease.
    Rassi FM; Minohara L; Rassi A; Correia LCL; Marin-Neto JA; Rassi A; da Silva Menezes A
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1213-1223. PubMed ID: 31648747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Shock as a determinant of poor patient-centered outcomes in implantable cardioverter defibrillator patients: is there more to it than meets the eye?
    Pedersen SS; Van Den Broek KC; Van Den Berg M; Theuns DA
    Pacing Clin Electrophysiol; 2010 Dec; 33(12):1430-6. PubMed ID: 20663070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Midlands Trial of Empirical Amiodarone versus Electrophysiology-guided Interventions and Implantable Cardioverter-defibrillators (MAVERIC): a multi-centre prospective randomised clinical trial on the secondary prevention of sudden cardiac death.
    Lau EW; Griffith MJ; Pathmanathan RK; Ng GA; Clune MM; Cooper J; Marshall HJ; Forsey PR; Stafford PJ; Gray RG; Skehan JD; Garratt CJ
    Europace; 2004 Jul; 6(4):257-66. PubMed ID: 15172648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete?
    Cooley R; Akhtar M; Sra J
    Curr Cardiol Rep; 1999 Nov; 1(4):268-73. PubMed ID: 10980853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life in the Canadian Implantable Defibrillator Study (CIDS).
    Irvine J; Dorian P; Baker B; O'Brien BJ; Roberts R; Gent M; Newman D; Connolly SJ
    Am Heart J; 2002 Aug; 144(2):282-9. PubMed ID: 12177646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study.
    Kowey PR; Crijns HJ; Aliot EM; Capucci A; Kulakowski P; Radzik D; Roy D; Connolly SJ; Hohnloser SH;
    Circulation; 2011 Dec; 124(24):2649-60. PubMed ID: 22082672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of the evidence on the effects and costs of implantable cardioverter defibrillator therapy in different patient groups, and modelling of cost-effectiveness and cost-utility for these groups in a UK context.
    Buxton M; Caine N; Chase D; Connelly D; Grace A; Jackson C; Parkes J; Sharples L
    Health Technol Assess; 2006 Aug; 10(27):iii-iv, ix-xi, 1-164. PubMed ID: 16904046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A guide to device selection: cardiac resynchronization therapy alone or in combination with an implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2003; 4 Suppl 2():S47-54. PubMed ID: 12776013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.